Victoria Smarodina, chief financial officer of the company, "Pharmak": "In the past 6 years, we have audited the consolidated financial statements. This year, the company management decided on disclosure statements for 2012. Thus, we demonstrate not only our responsibility according to Ukrainian legislation, but also respect us identified in the strategy of the provisions on transparency of doing business. "
The consolidated IFRS financial statements "Pharmak" was held on one of the "big four" — ZAO "Deloitte &Touche Yukreynian Services Company." Independent auditors' report contains an unqualified opinion on the consolidated IFRS financial statements "Farmak".
According to the consolidated financial statements of net sales in 2012 of USD 1,692,000, which is 15.2% higher than in 2011 (1,468,000 USD). Net income for 2012 is 278 million USD compared to 248 million USD in 2011.